Progenesis is a San Diego-based company founded in 2015 that develops and offers non-invasive genetic tests
for patients on their family planning journey. We offer a variety of services that can be customized to meet
the needs of every patient we serve. The Progenesis team is a motivated group of genetic specialists,
researchers, laboratory professionals, and analysts who are passionate about improving our patients' lives.
As pioneers in genetic screening technologies, our scientists are constantly pursuing research initiatives
to advance our services and expand our understanding of human genetics.
Address: 4150 Regents Park Row Suite 245
La Jolla, CA 92037
Previda®-DX is a personalized test tailored to patients’ specific genetic background. Patients interested in Previda®-DX are required to provide a report of their genetic records to assess if the test can be performed. After reviewing the patient’s gene report, scientists at Progenesis design a test to detect the mutation or rearrangement. Our team of laboratory technicians will optimize the test by using parental DNA to confirm the abnormality. The final test is performed on a biopsy from the embryo and includes testing for the specific mutation and/or chromosomal rearrangement in the embryo (PGT-M and PGT-SR) as well as 24-chromosome screening for aneuploidies (PGT-A).
Progenesis is the first company in the U.S. to use next generation sequencing (NGS) technology for preimplantation genetic diagnosis (PGT-M and PGT-SR). NGS is far superior to the current industry standard (real-time PCR).
NGS combines the power of single mutation detection and complete 24-chromosome screening. In addition, NGS offers the most accurate and sensitive technology to screen for unbalanced translocation events which are difficult to detect using traditional PCR and fluorescent in-situ hybridization based techniques.